Dana-Farber president announces intention to step down, successor named
Click Here to Manage Email Alerts
Laurie H. Glimcher, MD, announced her intention to step down as president and CEO of Dana-Farber Cancer Institute on Oct. 1.
Glimcher — who also has served as director of Dana-Farber/Harvard Cancer Center, as well as professor of medicine at Harvard Medical School — will assume the title of president emerita at Dana-Farber.
Glimcher, the first woman to serve as president and CEO of Dana-Farber, began her term in 2016. Since then, patient volume at the institution grew by 51%, and grant- and industry-funded research support increased by 62%, according to a press release from the institution.
“Eight years ago, I began this journey with a deep appreciation for the extraordinary research that emanated from Dana-Farber since its earliest days and the clinical excellence that Dana-Farber provides patients and families,” Glimcher said in the release. “Now, as I reflect on my tenure, I am intensely proud of what we have achieved in providing world-class care for our patients, leading in innovation, and discovering new treatments and cures. This is the perfect time for me to pass the leadership of this remarkable institution on to the next generation, and return my focus to cancer immunology research."
Benjamin Levine Ebert, MD, PhD, chair of Dana-Farber’s department of medical oncology, will succeed Glimcher as president and CEO.
Ebert oversees a research laboratory that focuses on the molecular basis of and treatment of blood cancers and their nonmalignant precursor conditions, with an emphasis on clonal hematopoiesis and myelodysplastic syndrome.
He also serves as professor of medicine at Harvard Medical School, a Howard Hughes Medical Institute investigator, and an institute member of the Broad Institute of MIT and Harvard.
“I’m extraordinarily honored to be selected as the next president and CEO of Dana-Farber and to build on the exceptional leadership and accomplishments of Laurie Glimcher,” Ebert said in the release. “Dana-Farber is truly a remarkable organization and a global leader in innovation, and in caring and advocating for cancer patients. Together with our executive leadership team, I will continue to advance a patient-first model as we open this new chapter.”
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts